IceCure Medical Ltd (Nasdaq: ICCM), a developer of minimally-invasive cryoablation technology, announced on Friday that it received a positive vote from the FDA's Medical Device Advisory Committee Panel, with 9 out of 14 panelists supporting the benefit-risk profile of its ProSense Cryoablation System for treating early-stage low-risk invasive breast cancer.
Panelists in favor indicated that ProSense's benefits outweigh its risks when combined with adjuvant endocrine therapy. Three dissenting voters noted that adequate special controls could have swayed their support.
The panel's decision was informed by data from IceCure's ICE3 study and comparisons to lumpectomy, as well as testimonies from patients, advocates and healthcare professionals.
ProSense offers a minimally invasive alternative to traditional surgery, leveraging liquid nitrogen to destroy tumours effectively.
A final FDA decision on ProSense's marketing authorization is anticipated in Q1 2025.
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Psilera collaborates with Hesperos for PSIL-006 preclinical modelling for frontotemporal dementia
Myosin Therapeutics' MT-125 cleared by US FDA to initiate first-in-human trial in glioblastoma
Ondine's Steriwave proven effective against deadly Mucor fungus
AB Science receives EMA approval to extend Masivet shelf life to four years
Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
NRx Pharmaceuticals files ANDA for preservative-free IV ketamine
Innovent's IBI363 granted second breakthrough therapy designation in China
Implantica reports positive NICE guidance for RefluxStop procedure in UK hospitals